These results indicate that mediators encoding genes with prognostic and predictive scores may guide further to understand the clinical importance and design new drugs that target secretory mediators in breast cancer distant metastasis, explicitly in aggressive subtypes TNBC or HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.